VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Elizabeth Smyth, Maren Knödler, Anne Giraut, Murielle Mauer, Magnus Nilsson, Nicole Van Grieken, Anna Dorothea Wagner, Markus Moehler, Florian Lordick, Elizabeth Smyth, Maren Knödler, Anne Giraut, Murielle Mauer, Magnus Nilsson, Nicole Van Grieken, Anna Dorothea Wagner, Markus Moehler, Florian Lordick

Abstract

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or esophageal adenocarcinoma will be randomized to either adjuvant chemotherapy (as before surgery) or to immunotherapy with nivolumab and low dose ipilimumab (nivolumab 3 mg/kg IV Q2W plus Ipilimumab 1 mg/kg IV Q6W for 1 year). The primary endpoint of the study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life. This is an open label randomized controlled multi-center phase-2 superiority trial. Patients will be randomized in a 1:1 ratio to study arms. The trial will recruit 240 patients; recruitment commenced July 2019 and is anticipated to take 30 months. Detailed inclusion/exclusion criteria, toxicity management guidelines, and statistical plans for EORTC VESTIGE are described in the manuscript. Clinical Trial Registration: The trial is registered with www.ClinicalTrials.gov, identifier: NCT03443856.

Keywords: adjuvant; chemotherapy; gastric cancer; gastroesophageal cancer; immunotherapy; ipilimumab; nivolumab; perioperative.

Copyright © 2020 Smyth, Knödler, Giraut, Mauer, Nilsson, Van Grieken, Wagner, Moehler and Lordick.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7002471/bin/fonc-09-01320-g0001.jpg

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
    1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. (2008) 358:36–46. 10.1056/NEJMoa073149
    1. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. (2013) 14:490–9. 10.1016/S1470-2045(13)70102-5
    1. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. (2019) 393:1948–57. 10.1016/S0140-6736(18)32557-1
    1. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. . Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2016) 27:v38–49. 10.1093/annonc/mdw350
    1. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2016) 27:v50–7. 10.1093/annonc/mdw329
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. (2006) 355:11–20. 10.1056/NEJMoa055531
    1. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. (2011) 29:1715–21. 10.1200/JCO.2010.33.0597
    1. Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, et al. . Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. (2016) 34:2721–7. 10.1200/JCO.2015.65.7692
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. (2009) 27:5062–7. 10.1200/JCO.2009.22.2083
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. (2015) 373:1627–39. 10.1056/NEJMoa1507643
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. (2015) 373:23–34. 10.1056/NEJMoa1504030
    1. (accessed 29 Novermber 1914).
    1. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. . Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. (2017) 390:2461–71. 10.1016/S0140-6736(17)31827-5
    1. Boku N, Kang Y, Satoh T, Chao Y, Kato K, Chung HC, et al. 617OA phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol. (2017) 28 (Suppl_5):v209–68. 10.1093/annonc/mdx369.001
    1. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. . CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. (2018) 36:2836–44. 10.1200/JCO.2017.76.6212
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. . Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. (2015) 372:2521–32. 10.1056/NEJMoa1503093
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. . Pembrolizumab versus chemotherapy for PD-L1- positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. 10.1056/NEJMoa1606774
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. (2015) 372:2509–20. 10.1056/NEJMoa1500596
    1. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. (2018) 4:e180013. 10.1001/jamaoncol.2018.0013
    1. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl. Acad Sci USA. (2010) 107:4275–80. 10.1073/pnas.0915174107
    1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. (2013) 369:122–33. 10.1056/NEJMoa1302369
    1. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. . Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. (2016) 17:1558–68. 10.1016/S1470-2045(16)30366-7
    1. Hodi FS, Postow MA, Chesney JA, Pavlic AC, Robert C, Grossmann KF, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. J Clin Oncol. (2015) 33(Suppl 15):9004 10.1200/jco.2015.33.15_suppl.9004
    1. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. . Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. (2017) 35:3815–22. 10.1200/JCO.2016.72.1167
    1. Reck M, Helmann MD, Paz-Ares L. G., Ramalingam SS, Brahmer JR, O'Byrne KJ, et al. Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Safety Analysis and Patient-Reported Outcomes From CheckMate 227. ASCO (2018). 10.1200/JCO.2018.36.15_suppl.9020
    1. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. (2008) 26:2006–12. 10.1200/JCO.2007.14.9898
    1. Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. . Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. (2017) 18:357–70. 10.1016/S1470-2045(17)30043-8
    1. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. (2009) 250:187–96. 10.1097/SLA.0b013e3181b13ca2

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere